Equillium (EQ) Competitors $0.72 +0.02 (+2.86%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends EQ vs. KZR, INMB, COYA, MNPR, NVCT, EPRX, ANIX, KPTI, ELYM, and CHRSShould you be buying Equillium stock or one of its competitors? The main competitors of Equillium include Kezar Life Sciences (KZR), INmune Bio (INMB), Coya Therapeutics (COYA), Monopar Therapeutics (MNPR), Nuvectis Pharma (NVCT), Eupraxia Pharmaceuticals (EPRX), Anixa Biosciences (ANIX), Karyopharm Therapeutics (KPTI), Eliem Therapeutics (ELYM), and Coherus BioSciences (CHRS). These companies are all part of the "pharmaceutical products" industry. Equillium vs. Kezar Life Sciences INmune Bio Coya Therapeutics Monopar Therapeutics Nuvectis Pharma Eupraxia Pharmaceuticals Anixa Biosciences Karyopharm Therapeutics Eliem Therapeutics Coherus BioSciences Equillium (NASDAQ:EQ) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, community ranking, earnings, analyst recommendations and valuation. Do analysts rate EQ or KZR? Equillium presently has a consensus price target of $5.00, suggesting a potential upside of 596.28%. Kezar Life Sciences has a consensus price target of $40.50, suggesting a potential upside of 440.72%. Given Equillium's stronger consensus rating and higher probable upside, equities analysts clearly believe Equillium is more favorable than Kezar Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Equillium 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Kezar Life Sciences 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the MarketBeat Community prefer EQ or KZR? Kezar Life Sciences received 100 more outperform votes than Equillium when rated by MarketBeat users. However, 83.72% of users gave Equillium an outperform vote while only 57.38% of users gave Kezar Life Sciences an outperform vote. CompanyUnderperformOutperformEquilliumOutperform Votes3683.72% Underperform Votes716.28%Kezar Life SciencesOutperform Votes13657.38% Underperform Votes10142.62% Does the media refer more to EQ or KZR? In the previous week, Kezar Life Sciences had 3 more articles in the media than Equillium. MarketBeat recorded 9 mentions for Kezar Life Sciences and 6 mentions for Equillium. Kezar Life Sciences' average media sentiment score of 0.46 beat Equillium's score of 0.38 indicating that Kezar Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Equillium 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kezar Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Is EQ or KZR more profitable? Kezar Life Sciences has a net margin of 0.00% compared to Equillium's net margin of -10.05%. Equillium's return on equity of -20.68% beat Kezar Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Equillium-10.05% -20.68% -10.77% Kezar Life Sciences N/A -54.95%-46.11% Which has preferable earnings & valuation, EQ or KZR? Equillium has higher revenue and earnings than Kezar Life Sciences. Equillium is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEquillium$36.08M0.71-$13.34M-$0.14-5.13Kezar Life Sciences$7M7.81-$101.87M-$13.18-0.57 Do institutionals & insiders hold more shares of EQ or KZR? 27.1% of Equillium shares are owned by institutional investors. Comparatively, 67.9% of Kezar Life Sciences shares are owned by institutional investors. 30.3% of Equillium shares are owned by insiders. Comparatively, 9.3% of Kezar Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more volatility & risk, EQ or KZR? Equillium has a beta of 1.83, indicating that its stock price is 83% more volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. SummaryEquillium beats Kezar Life Sciences on 11 of the 18 factors compared between the two stocks. Ad Wyatt Investment ResearchMy #1 Pre IPO Trade for 2025 – NAME and TICKEROne tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...The Next SpaceX Pre-IPO Get Equillium News Delivered to You Automatically Sign up to receive the latest news and ratings for EQ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EQ vs. The Competition Export to ExcelMetricEquilliumPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.44M$6.41B$5.01B$8.81BDividend YieldN/A8.11%5.16%4.06%P/E Ratio-5.1310.57134.3717.77Price / Sales0.71243.641,158.6875.18Price / CashN/A22.1633.5332.53Price / Book1.125.474.674.68Net Income-$13.34M$153.61M$119.07M$226.08M7 Day Performance4.95%-2.00%-1.83%-1.04%1 Month Performance-35.88%-7.47%-3.62%1.04%1 Year Performance43.97%31.80%31.63%26.28% Equillium Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EQEquillium3.1956 of 5 stars$0.72+2.9%$5.00+596.3%+43.6%$25.44M$36.08M-5.1340Analyst RevisionKZRKezar Life Sciences4.3591 of 5 stars$7.49+1.5%$40.50+440.7%-15.4%$53.85M$7M0.0060Analyst RevisionINMBINmune Bio2.2804 of 5 stars$4.56-3.2%$20.00+338.6%-39.1%$101.10M$42,000.00-2.1110COYACoya Therapeutics3.0403 of 5 stars$6.03-0.7%$16.67+176.4%+10.6%$100.74M$9.55M-9.286MNPRMonopar Therapeutics3.5846 of 5 stars$19.00-0.1%$27.33+43.9%+1,213.5%$100.33MN/A0.0010Gap UpNVCTNuvectis Pharma3.2986 of 5 stars$5.07-1.4%$21.00+314.2%-38.8%$99.31MN/A0.008EPRXEupraxia Pharmaceuticals2.4867 of 5 stars$3.62+11.0%$9.00+148.6%N/A$98.75MN/A-5.0329Gap UpHigh Trading VolumeANIXAnixa Biosciences2.8707 of 5 stars$3.05-2.6%$7.00+129.9%+2.9%$97.99M$210,000.00-7.815Analyst ForecastNews CoverageKPTIKaryopharm Therapeutics3.9896 of 5 stars$0.78flat$5.00+545.2%-1.5%$96.87M$146.03M0.00380ELYMEliem TherapeuticsN/A$3.25+6.2%N/A+28.0%$96.69MN/A-6.1320CHRSCoherus BioSciences3.8225 of 5 stars$1.10+34.1%$6.13+456.8%-46.9%$94.65M$304.34M-13.75246High Trading Volume Related Companies and Tools Related Companies Kezar Life Sciences Competitors INmune Bio Competitors Coya Therapeutics Competitors Monopar Therapeutics Competitors Nuvectis Pharma Competitors Eupraxia Pharmaceuticals Competitors Anixa Biosciences Competitors Karyopharm Therapeutics Competitors Eliem Therapeutics Competitors Coherus BioSciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EQ) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Equillium, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Equillium With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EQ Stock Alerts